Market revenue in 2023 | USD 119.3 million |
Market revenue in 2030 | USD 212.0 million |
Growth rate | 8.6% (CAGR from 2023 to 2030) |
Largest segment | Hereditary non-cancer testing |
Fastest growing segment | Hereditary Non-cancer Testing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hereditary Cancer Testing, Hereditary Non-cancer Testing |
Key market players worldwide | Myriad Genetics Inc, Invitae Corp, Illumina Inc, Natera Inc, Labcorp Holdings Inc, Roche Holding AG ADR, Quest Diagnostics Inc, CooperSurgical, Agilent Technologies Inc, Thermo Fisher Scientific Inc, Twist Bioscience Corp, Sophia Genetics SA, Fulgent Genetics Inc, MedGenome, Centogene NV Ordinary Shares, The Cooper Companies Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary testing market will help companies and investors design strategic landscapes.
Hereditary non-cancer testing was the largest segment with a revenue share of 86.42% in 2023. Horizon Databook has segmented the South Korea hereditary testing market based on hereditary cancer testing, hereditary non-cancer testing covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea's hereditary testing market is driven by ongoing expansion of NIPTs by local and international players. In December 2019, Roche Diagnostics Korea announced that it would promote application of NIPT in Korea.
In 2016, it introduced an NIPT solution, Harmony, which implemented a test-and-send-out approach to send extracted samples to U.S. test institutions and receive results. To improve NIPTs in Korea, the company would have to directly conduct these tests, thereby saving time and costs.
NIPT based on digital PCR developed by Korean company BioCore is increasingly being adopted by research studies to screen trisomy 21, due to its high sensitivity and real-time diagnosis to help overcome challenges faced in sequence-based analysis.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea hereditary testing market, including forecasts for subscribers. This country databook contains high-level insights into South Korea hereditary testing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account